You're correct, Chemdeps...
The idea, per Leo, is to License B in order to fund K and P. What is unknown is whether the license will be for one indication, or the entire B platform. Value changes exponentially between the two.
I was directing my scorn towards the folks that are predicting a full buyout by next year.
No. That will not happen.
I will give some credence to the idea of a buyout MUCH further down the road, when the pipeline is flushed out more, but not before then.
Brilacidin, acquired for peanuts remember, is the Cellceutix equivalent of a "flip." It will free them from Aspire, while allowing for the continuation of other trials, and provide delicious revenue in the form of upfronts, milestones, and eventual royalties, and all within 2 years of the "heist."
Brilliant if you ask me. You didn't, but brilliant nonetheless.
Market Data 
Markets 
AI
